XBridge® and ACQUITY UPLC® Oligonucleotide C18 Columns
XBridge® and ACQUITY UPLC® Oligonucleotide C18 Columns for Synthetic Oligonucleotide Analysis and PurificationIon-pair, reversed-phase separation of detritylated oligonucleotides on sub-3 micron particles yields exceptional component resolution.UPLC ® technology increases sample throughput while maintaining necessary oligonucleotide component resolution.LC/UV and LC/MS methods for enhanced quantitative and qualitative oligonuc…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Nice column for basic compounds
Active pharmaceutical ingredient products
It is more effective and simply using active pharmaceutical ingredient product and basic compounds are preferred for xbridge column and reputability and compare to other columns these are the rugged columns.
Review Date: 5 Feb 2018 | Waters
Chromatography
This column has good separation and high resolution at different conditions. The new stationary phase provide for various chromatographic application. My next research I will be use it. I recommend this product to all my colleague.
Review Date: 25 Mar 2014 | Waters
Robust column, high pH range.
Review Date: 20 Sept 2011 | Waters
XBridge® and ACQUITY UPLC® Oligonucleotide C18 Columns for Synthetic Oligonucleotide Analysis and Purification
- Ion-pair, reversed-phase separation of detritylated oligonucleotides on sub-3 micron particles yields exceptional component resolution.
- UPLC ® technology increases sample throughput while maintaining necessary oligonucleotide component resolution.
- LC/UV and LC/MS methods for enhanced quantitative and qualitative oligonucleotides analyses.
- Various XBridge™ Oligonucleotide C 18 column dimensions address lab scale purification needs.
- 2nd generation hybrid-silica BEH Technology™ particles deliver exceptional column life.
Use of synthetic oligonucleotides for research, diagnostic, and therapeutic applications continues to increase. The availability of 2.5 μm HPLC or 1.7 μm UPLC ® technology particles in several column dimensions provides flexibility to meet various LC/UV or LC/MS application needs. Waters' stringent manufacturing and quality control procedures help ensure consistent batch-to-batch and column-to-column performance.
Brochures
Acquity UPLC Columns Brochure
When investing in a new LC instrument, it is important to consider its capabilities to meet existingand future demand. With UPLC Technology, one can invest in the future by utilizing a single system with the capabaility to optimally run sub-2μm UPLC Columns with the ruggedness and robustness to run legacy HPLC methods. The ACQUITY UPLC® System family is an LC Technology platform that can be utilized independent of your separation needs, thus facilitating productivity and simplifying method transfer from site to site.
An automated, compliance-ready LC-MS workflow for intact mass confirmation and purity analysis of oligonucleotides
Oligonucleotide therapeutics have emerged in recent years as a powerful alternative to small molecule and protein therapeutics. Manufacturing and quality control of oligonucleotide therapeutics requires highly selective and sensitive LC-MS methods. The method often used for mass spectrometry-based oligonucleotide analysis has been reversed-phase chromatography employing a variety of ion-pairing reagents and modifiers in negative ESI-MS mode. Integrated LC-MS workflows for oligonucleotide analysis have been recently implemented on quadrupole and QTof LC-MS platforms.
Advancing Host Cell Protein Analyses Through the Combined Use of Microscale 2D RP/RP with CSH C<sub>18</sub> and Ion Mobility Enabled MS Detection
In this application note, recent advances in microscale peptide chromatography are applied to HCP analysis. The novel charge-surface-modified C18 material, known as CSH C18, which can produce high peptide peak capacities even at high mass loads, is used in the format of a 15K psi capable 300 μm I.D. column along with an ACQUITY UPLC M-Class based 2D-RP/RP system and SYNAPT HDMSE detection to provide a robust analytical workflow for the identification of low concentrations of HCP impurities at single digit PPM levels (parts per million, or ng/mg).
Waters ACQUITY PREMIER Columns set a new standard of performance for chromatographic analyses
Novel column technology designed to put disease research and drug development on a more productive and efficient path
